Trial Profile
Immunogenicity and safety in children 1 - 9 years of a vaccine against meningococcal serogroup C strain 2135 produced with tetanus toxoid conjugate
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Apr 2011
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine group C conjugate (Primary)
- Indications Meningococcal group C infections
- Focus Pharmacodynamics
- 27 Apr 2011 New trial record